Has Saravut Weroha, MD received payments from drug or device companies?

Yes. Drug and device makers reported $147,869 in general payments to Saravut Weroha, MD across 25 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Saravut Weroha, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Saravut Weroha, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Saravut Weroha, MD

Medical Oncology · Rochester, MNNPI 1043415144

Payments from drug & device makers

$147,869in general payments, 2019–2025

Across 25 payments — averaging $5914.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$118K
Pfizer$12K
Merck$10K
AstraZeneca$5K
AbbVie$2K
Eli Lilly$1K
plus $152 from 2 others

$1,270in research payments, 2019–2025

Across 2 payments — averaging $635.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$1K

What the payments were for

Consulting fees$15,80987%
Travel & lodging$1,6169%
Food & beverage$6644%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	2	$117,940
Pfizer	2	$11,841
Merck	12	$9,911
AstraZeneca	3	$4,507
AbbVie	2	$2,465
Eli Lilly	2	$1,053
Genentech USA, Inc.	1	$102
Immunogen, Inc.	1	$50

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LYNPARZA$4,453
Elahere$2,465
Avastin$102

How this compares

$147,869 in reported general payments places this provider in the 45th percentile of 133 medical oncology providers in Minnesota.

See all medical oncology providers in Minnesota →

Medicare billing

Part B allowed, 2024

$885,859

Medicare patients

196

Services billed

27,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prochlorperazine Maleate	27	$326
Ondansetron Hcl	23	$310
Olanzapine	19	$270
Dexamethasone	40	$222

Paid to pharmacies, not to this prescriber.

Other medical oncology in Rochester

Evanthia GalanisRochester$72.3M
Frank SinicropeRochester$10.3M
Harry YoonRochester$10.2M
Konstantinos LeventakosRochester$9.6M
Matthew BlockRochester$8.1M
Keith BibleRochester$7.5M
Jian CampianRochester$7.3M
Katharine PriceRochester$7M
Robert McWilliamsRochester$6.3M
Elisabeth HeathRochester$6.2M

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →